Logo image of ELEV

ELEVATION ONCOLOGY INC (ELEV) Stock Fundamental Analysis

NASDAQ:ELEV - Nasdaq - US28623U1016 - Common Stock - Currency: USD

0.3609  -0.02 (-4.55%)

Fundamental Rating

2

ELEV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. The financial health of ELEV is average, but there are quite some concerns on its profitability. ELEV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELEV has reported negative net income.
In the past year ELEV has reported a negative cash flow from operations.
ELEV had negative earnings in each of the past 5 years.
In the past 5 years ELEV always reported negative operating cash flow.
ELEV Yearly Net Income VS EBIT VS OCF VS FCFELEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -46.52%, ELEV is in line with its industry, outperforming 51.06% of the companies in the same industry.
ELEV's Return On Equity of -74.11% is in line compared to the rest of the industry. ELEV outperforms 54.75% of its industry peers.
Industry RankSector Rank
ROA -46.52%
ROE -74.11%
ROIC N/A
ROA(3y)-66.25%
ROA(5y)-48.31%
ROE(3y)-117.18%
ROE(5y)-79.52%
ROIC(3y)N/A
ROIC(5y)N/A
ELEV Yearly ROA, ROE, ROICELEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELEV Yearly Profit, Operating, Gross MarginsELEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

ELEV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ELEV has been increased compared to 5 years ago.
The debt/assets ratio for ELEV has been reduced compared to a year ago.
ELEV Yearly Shares OutstandingELEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELEV Yearly Total Debt VS Total AssetsELEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

ELEV has an Altman-Z score of -3.55. This is a bad value and indicates that ELEV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ELEV (-3.55) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.52 indicates that ELEV is somewhat dependend on debt financing.
The Debt to Equity ratio of ELEV (0.52) is worse than 74.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -3.55
ROIC/WACCN/A
WACCN/A
ELEV Yearly LT Debt VS Equity VS FCFELEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

ELEV has a Current Ratio of 21.21. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ELEV (21.21) is better than 95.95% of its industry peers.
ELEV has a Quick Ratio of 21.21. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
ELEV has a Quick ratio of 21.21. This is amongst the best in the industry. ELEV outperforms 95.95% of its industry peers.
Industry RankSector Rank
Current Ratio 21.21
Quick Ratio 21.21
ELEV Yearly Current Assets VS Current LiabilitesELEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

ELEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.06%, which is quite impressive.
EPS 1Y (TTM)47.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELEV will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.56% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.79%
EPS Next 2Y9.13%
EPS Next 3Y1.14%
EPS Next 5Y16.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELEV Yearly Revenue VS EstimatesELEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
ELEV Yearly EPS VS EstimatesELEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELEV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELEV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELEV Price Earnings VS Forward Price EarningsELEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELEV Per share dataELEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.13%
EPS Next 3Y1.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEVATION ONCOLOGY INC

NASDAQ:ELEV (4/22/2025, 12:24:08 PM)

0.3609

-0.02 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners56.05%
Inst Owner Change-0.22%
Ins Owners0.27%
Ins Owner Change0.56%
Market Cap21.37M
Analysts75.71
Price Target2.09 (479.11%)
Short Float %16.46%
Short Ratio3.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-8.46%
Max EPS beat(2)20.91%
EPS beat(4)2
Avg EPS beat(4)5.51%
Min EPS beat(4)-11.52%
Max EPS beat(4)21.12%
EPS beat(8)4
Avg EPS beat(8)4.36%
EPS beat(12)4
Avg EPS beat(12)-3.76%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-70.71%
PT rev (3m)-70.71%
EPS NQ rev (1m)6.66%
EPS NQ rev (3m)21.13%
EPS NY rev (1m)27.15%
EPS NY rev (3m)28.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.52%
ROE -74.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.25%
ROA(5y)-48.31%
ROE(3y)-117.18%
ROE(5y)-79.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.21
Quick Ratio 21.21
Altman-Z -3.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
EPS Next Y16.79%
EPS Next 2Y9.13%
EPS Next 3Y1.14%
EPS Next 5Y16.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.27%
OCF growth 3YN/A
OCF growth 5YN/A